CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) today announced the closing of a
registered underwritten public offering of its common stock, which
included the sale of additional shares of common stock upon full
exercise of the underwriter’s option to purchase additional shares.
Total proceeds for the offering were $57.5 million, before deducting
estimated offering expenses payable by Cerus.
BTIG, LLC acted as sole book-running manager for the offering.
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was declared
effective by the Securities and Exchange Commission (SEC) on January 8,
2018. You should read the prospectus in the registration statement and
related final prospectus supplement that Cerus has filed with the SEC
for more complete information about Cerus and this offering. An
electronic copy of the final prospectus supplement and accompanying
prospectus relating to the offering is available on the website of the
SEC at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to the offering may be obtained by contacting BTIG,
LLC, at 825 Third Avenue, 6th Floor, New York, NY, 10022, or by
telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in the United
States, Europe, the Commonwealth of Independent States, the Middle East
and selected countries in other regions around the world. The INTERCEPT
Red Blood Cell system is in clinical development.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Forward-Looking Statements
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to Cerus’ public
offering. These forward-looking statements are based upon Cerus’ current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including,
without limitation, risks related to market conditions and the
satisfaction of customary closing conditions related to the proposed
public offering, risks related to the application of the net proceeds
from the proposed public offering, risks associated with the uncertain
research and product development process, and other risks detailed in
Cerus' filings with the SEC, including in Cerus' quarterly report on
Form 10-Q for the quarter ended September 30, 2017, filed with the SEC
on November 3, 2017 and in the final prospectus supplement related to
the proposed offering filed with the SEC on February 1, 2018. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Cerus
does not undertake any obligation to update any forward-looking
statements as a result of new information, future events, changed
assumptions or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180202005593/en/
Source: Cerus Corporation